Breastfeeding may reduce depression 10 years after giving birth

Breastfeeding may significantly lower the likelihood women experience depression and anxiety 10 years after giving birth.
Researchers also observed a dose-response relationship, as women who breastfed for longer periods had lower odds for these mental health conditions, and those who breastfed for at least 12 months decreased their likelihood of depression and anxiety more than 60%.
“The idea that something so natural and accessible could reduce anxiety and depression in women is very exciting,” Fionnuala M. McAuliffe, MD, honorary fellow of ACOG, head of women’s and child’s health and director

Q&A: Protection pointers as ICE activity increases in health care settings

Health care providers may encounter immigration officers in their hospitals and practices, but they can take steps to prepare themselves for these interactions, staying safe and legally compliant, according to an expert.
The past year has been marked by news of mass deportations and Immigration Customs Enforcement (ICE) raids across the United States, some of which have turned violent, even deadly.
Tensions have heightened in the last few weeks with killings that led to protests in Minnesota, and then nationwide. On Jan. 20, physicians in Minnesota held a press conference to detail their

GIs comfortable using mirikizumab earlier in ulcerative colitis

LAS VEGAS — More than a quarter of patients with ulcerative colitis do not receive prior advanced therapy before initiating mirikizumab, according to real-world data presented at Crohn’s & Colitis Congress.
Results from a retrospective, observational study also showed oral corticosteroid use declined by more than half in the 3 months after mirikizumab (Omvoh, Eli Lilly & Co.) initiation, indicating improved disease control.
“This study offers the first real-world snapshot of U.S. patients receiving mirikizumab, revealing its use across diverse patients, including those advanced

New guideline delineates stroke treatment for children

The American Heart Association and American Stroke Association have issued an updated guideline for the diagnosis and treatment of acute ischemic stroke.
The new guideline, published in Stroke, replaces the version published in 2018 and updated in 2019, and features considerations for systems utilizing mobile stroke units; recommendations for early detection and management of stroke; and, for the first time, guidance for the emergency management of stroke in children.
The document was endorsed by the American Association of Neurological Surgeons/Congress of Neurological Surgeons, Neurocritical

Pharmacologic agents for refractive correction take center stage

A new treatment vertical in eye care, pharmacologic agents for refractive correction, is in the early stage of commercialization and will grow significantly over the next decade.
In the lead are several miotic eye drops for enhancing near vision in the presbyope. We now have four commercial products approved, Vuity (pilocarpine HCl ophthalmic solution 1.25%) from AbbVie, Qlosi (pilocarpine hydrochloride ophthalmic solution 0.4%) from Orasis, Vizz (aceclidine ophthalmic solution 1.44%) from Lenz and Yuvezzi (carbachol 2.75%/brimonidine tartrate 0.1% ophthalmic solution) from Tenpoint. All four

Q&A: Skin punch biopsy aims to detect autism spectrum disorder close to birth

Research from NeuroQure, a biotechnology company specializing in autism spectrum disorder, has led to the development of a skin punch biopsy that can be used as early as the second day after birth to detect the condition.
Healio spoke to John “Jay” Gargus, MD, PhD, founding scientist and chief scientific officer at NeuroQure and professor emeritus of physiology, biophysics, pediatric medical genetics and genomics at the University of California, Irvine, about the genesis of this early testing method and the implications for patients, families and clinical practice.
Healio: Why is there a need

Q&A: HIV drug may be key to halting glioblastoma cell growth

Brain cells that promote tumor expansion for aggressive cancers such as glioblastoma can be “flipped” to instead inhibit that growth and potentially halt their spread, according to a study published in Neuron.
Healio spoke with Sheila K. Singh, MD, PhD, FRCSC, study author, professor and head, neurosurgery, professor of biochemistry and biomedical Sciences and a pediatric neurosurgeon at McMaster Children’s Hospital in Hamilton, Ontario, Canada, to find out how researchers plan to repurpose a novel therapeutic developed for HIV to stop glioblastoma in its tracks.
Healio: Why was glioblastoma of

Laboratory signs show early CKD risks for women with preeclampsia

Laboratory signs of chronic kidney disease were greater for women who had a pregnancy complicated by preeclampsia, according to study data published in the Journal of the American Society of Nephrology.
Studies have shown that women with preeclampsia may be at risk for developing kidney failure, but these risks can take years or decades to develop, according to Jennifer Yo, MBBS, MPH, PhD, nephrology staff specialist at Monash Health, Australia, and colleagues. However, clinical guidelines do not provide clear recommendations for tracking laboratory signs of kidney function for women with

Q&A: Home gardening, nutrition and women’s health

Susan Weiner, MS, RDN, CDN, CDCES, FADCES, talks with Stacey Woodson, MS, RDN, LDN, about how home gardening supports multiple dimensions of women’s health.
Weiner: What are the benefits of growing fruits and vegetables at home, including office, community garden and residential settings?
Woodson: Growing your own produce offers a multitude of measurable benefits that health care professionals can confidently recommend to patients.
Physically, having fresh fruits and vegetables at your fingertips increases accessibility, encouraging consumption of produce, which naturally boosts overall health

Nerve stimulator shows ongoing efficacy in rheumatoid arthritis

An implantable vagus nerve stimulation device yielded an ACR20 response rate of more than 52% at 12 months in patients with rheumatoid arthritis, according to findings published in Nature Medicine.
“Having a strong clinical investigator background and experience in clinical trials, I was particularly intrigued and curious to participate in such clinical efforts,” John R.P. Tesser, MD, FACP, MACR, of Arizona Arthritis & Rheumatology Associates and Midwestern University, told Healio. “To be clear, this would be the first RA phase 3 clinical trial of any device, and